In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-p...
In a Japanese phase II trial (MARBLE) reported in The Lancet Oncology, Shukuya et al evaluated a regimen of atezolizumab plus carboplatin/paclitaxel in patients with recurrent or metastatic thymic car...
Maybe skip the Friday surgery slot to avoid risks. Study suggests we should think before getting ink. Tiny water bears see a big cancer treatment win, and more this week!